Lamivir-S 40 is used to treat human immunodeficiency virus (HIV) infections in patients whose body weight is greater than 60kg. It contains 2 active ingredients: 150mg of lamivudine and 40mg of stavudine. Both of these components are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit the replication of HIV, which helps to maintain the viral load and manage active infections.
Take 1 tablet every 12 hours, with or without food. If you forget to take a dose, continue with your usual dose schedule without taking a double dose. Do not change your prescription without consulting your doctor.
If you are allergic to lamivudine, stavudine, or any of the other ingredients in Lamivir-S 40, do not use this medication.
Some of the reported side effects of Lamivir-S 40 include:
- Stuffy nose;
- Sore throat;
- And abnormal liver function test results.
Patients may also display more serious reactions, such as:
- Lactic acidosis, which is characterized by abdominal pain, nausea, vomiting, uneven heart rate, muscle cramps, unusual fatigue, and reduced appetite;
- And pancreas problems, which are characterized by dark-colored urine, clay-colored feces, jaundice, itching, and upper stomach pain.
These may not be all the side effects of Lamivir–S 40. Any adverse events should be reported immediately to a doctor.
Major health complications, such as lactic acidosis and severe hepatomegaly with steatosis were experienced by patients with poor health status when they were prescribed with nucleoside analogues. Patients with risk factors for lactic acidosis, such as having liver disorders, should use caution when considering this medication. If any of these risks apply to you, please consult your doctor to ensure your safety.
The presence of 2 different active ingredients in this medication increases its risk of undesirable drug interactions. Lamivudine can interact with interferon- and ribavirin-bases, resulting in hepatic decompensation that can be fatal. It can also react with zalcitabine, inhibiting intracellular phosphorylation. Additionally, stavudine can interact with zidovudine (another type of antiretroviral drug), resulting in the inhibition of the intracellular phosphorylation of stavudine. Another drug that may inhibit the intracellular phosphorylation of stavudine is doxorubicin. Therefore, if you are taking these medications, you must inform your doctor.
Pregnancy & Lactation
Both of the active ingredients in this medication, lamivudine and stavudine, are ranked as category C substances in the FDA’s Pregnancy Categories. As such, pregnant individuals should only take Lamivir-S 40 if its potential benefits outweigh any potential risks to their unborn children. It is also currently not known if these 2 antiretroviral components are excreted via breast milk. As such, breastfeeding mothers should consult a doctor about safe breastfeeding practices while using this medication.
If you accidentally overdose, seek immediate medical attention. Do not adjust your dose without discussing it with your doctor. If you require dose adjustments, this combination drug should not be used.
Alternative Brand Names
This antiretroviral medication is available worldwide, including the US and Canada, under the brand names Emduo 150mg/40mg and Lamistar 150mg/40mg.
Reviews are only written by verified customers who have purchased this product.